One step closer to the new frontiers of healthcare for cardiomyopathy patients

There were great advances in the treatment of heart failure (HF) over the past decades, characterised by the inclusion of ARNI and SGLT2 inhibitors in the latest guidelines. The use of cardiac myosin inhibitors specifically for patients with hypertrophic cardiomyopathy (HCM) is also making large steps forward, which reflects the next step towards more personalised treatment.1 The increasing repertoire of treatments makes it even more important to select those patients who will benefit the most from these therapies. However, the diagnostic markers to make this selection are still limited to the usual suspects: left ventricular ejection fraction, New York Heart Association (NYHA) class and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Better identification of those patients who are at high risk of deterioration, and would benefit the most from additional therapy, could reduce the burden of HCM and lower the need for hospitalisation and/or heart transplantation. Proteomics profiling allows...
Source: Heart - Category: Cardiology Authors: Tags: Editorials Source Type: research